Solution-Phase Synthesis of Neurotrophin Agonists Without Solid Supports
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthesis routes for small molecule agonists of neurotrophins, such as NGF and BDNF, are not suitable for large-scale industrial manufacturing and often require the use of solid supports, which can be inefficient and costly.
Innovation Solution
A novel synthesis process for compounds of formula FI, involving a series of reactions in organic solvents without the use of solid supports, including steps with specific temperature and solvent conditions, to produce high-purity compounds suitable for large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If solid phase synthesis with positional scanning format is used, then the synthesis can be performed with automated control, but the process requires 7 steps including cleavage from solid support which reduces productivity and increases complexity for large-scale manufacturing
Solution Approach 1:
The invention extracts and eliminates the solid support (Rink amide resin) from the synthesis process. By performing the synthesis in solution phase instead of solid phase, the process removes the need for cleavage steps and solid support handling, directly addressing the productivity and complexity issues while maintaining automated control capability through the standardized reaction sequence
Solution Approach 2:
The invention changes the physical state parameter of the synthesis from solid phase to solution phase. This parameter change fundamentally alters the process by eliminating the need for solid support attachment and cleavage, reducing the 7-step process to fewer steps while maintaining automated control, thereby improving productivity for large-scale manufacturing
2Manufacturing precision
If solid support (Rink amide resin) is used for synthesis, then the targeted molecule can be grown sequentially with controlled positioning, but the cleavage step to recover the molecule reduces manufacturing precision and increases process complexity
Solution Approach 1:
The invention removes the solid support system from the synthesis process. By using solution phase synthesis with protected amino acids and controlled coupling reactions, the process maintains sequential assembly precision without requiring solid support attachment and cleavage steps, thereby reducing process complexity
Solution Approach 2:
The invention uses protected amino acid derivatives that carry the necessary protecting groups as soluble intermediates. These protected compounds serve as soluble copies or proxies for the final deprotected amino acids, allowing sequential assembly in solution phase with the same precision as solid phase but without the complexity of solid support handling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new synthesis method allows for the production of high-purity small molecule agonists with minimal impurities, facilitating efficient and cost-effective industrial manufacturing.
Implementation Method 1
Reacting CS1 with CS2 in an organic solvent resulting in a compound CS4 of formula FCS4
Data Source
AI summary
The disclosure concerns a process for synthesizing a compound of formula FI:wherein:R1 is phenyl substituted with halogen or trifluoromethyl, and further optionally substituted with one or two substituents selected from the group consisting of halogen, (C1-C6)alkyl, (C1-C6)alkoxy, and halo(C1-C6)alkyl; or alternatively R1 is pyrrolidin-1-yl;R2 is 2-oxo-pyrrolidin-1-ylmethyl or sulfamoylphenyl; andR3 is chosen from propyl, 1-methylethyl, butyl, 2-methylpropyl, pentyl, 1-methyl-butyl, 2-methylbutyl, hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, and 1-methylpentyl.